Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases

J. Sany; J. M. Anaya; V. Lussiez; M. Couret; B. Combe; J. P. Daures

Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases

J. Sany, J. M. Anaya, V. Lussiez, M. Couret, B. Combe, J. P. Daures

Producción científica: Contribución a una revista › Artículo de Investigación › revisión exhaustiva

Resumen

One hundred and ninety-one patients with severe rheumatoid arthritis (RA) were included in a prospective open longterm study of the safety, efficacy and maintenance of methotrexate (MTX) treatment. The mean duration of MTX treatment was 19 ± 13.2 (3-58) months; the mean weekly dose of MTX was 10.2 ± 0.2 mg. Analysis of the 191 patients in an intent-to-treat manner showed a significant improvement of all the clinical variables and a decrease of erythrocyte sedimentation rate with a steroid sparing effect. The probability of continuing MTX therapy for up to 2 years was 65% and for up to 5 years was 46%. Adverse effects of MTX occurred in 37.1% of the patients, but only 15.7% discontinued MTX permanently.

Idioma original	Inglés estadounidense
Páginas (desde-hasta)	1323-1327
Número de páginas	5
Publicación	Journal of Rheumatology
Volumen	18
N.º	9
Estado	Publicada - 1991
Publicado de forma externa	Sí

Áreas temáticas de ASJC Scopus

Reumatología
Inmulogía y alergología
Inmunología

Otros archivos y enlaces

Citar esto

@article{3f0b1efc15c340b598706d5c7865ca26,

title = "Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases",

abstract = "One hundred and ninety-one patients with severe rheumatoid arthritis (RA) were included in a prospective open longterm study of the safety, efficacy and maintenance of methotrexate (MTX) treatment. The mean duration of MTX treatment was 19 ± 13.2 (3-58) months; the mean weekly dose of MTX was 10.2 ± 0.2 mg. Analysis of the 191 patients in an intent-to-treat manner showed a significant improvement of all the clinical variables and a decrease of erythrocyte sedimentation rate with a steroid sparing effect. The probability of continuing MTX therapy for up to 2 years was 65% and for up to 5 years was 46%. Adverse effects of MTX occurred in 37.1% of the patients, but only 15.7% discontinued MTX permanently.",

author = "J. Sany and Anaya, {J. M.} and V. Lussiez and M. Couret and B. Combe and Daures, {J. P.}",

year = "1991",

language = "English (US)",

volume = "18",

pages = "1323--1327",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "9",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis with methotrexate

T2 - A prospective open longterm study of 191 cases

AU - Sany, J.

AU - Anaya, J. M.

AU - Lussiez, V.

AU - Couret, M.

AU - Combe, B.

AU - Daures, J. P.

PY - 1991

Y1 - 1991

N2 - One hundred and ninety-one patients with severe rheumatoid arthritis (RA) were included in a prospective open longterm study of the safety, efficacy and maintenance of methotrexate (MTX) treatment. The mean duration of MTX treatment was 19 ± 13.2 (3-58) months; the mean weekly dose of MTX was 10.2 ± 0.2 mg. Analysis of the 191 patients in an intent-to-treat manner showed a significant improvement of all the clinical variables and a decrease of erythrocyte sedimentation rate with a steroid sparing effect. The probability of continuing MTX therapy for up to 2 years was 65% and for up to 5 years was 46%. Adverse effects of MTX occurred in 37.1% of the patients, but only 15.7% discontinued MTX permanently.

AB - One hundred and ninety-one patients with severe rheumatoid arthritis (RA) were included in a prospective open longterm study of the safety, efficacy and maintenance of methotrexate (MTX) treatment. The mean duration of MTX treatment was 19 ± 13.2 (3-58) months; the mean weekly dose of MTX was 10.2 ± 0.2 mg. Analysis of the 191 patients in an intent-to-treat manner showed a significant improvement of all the clinical variables and a decrease of erythrocyte sedimentation rate with a steroid sparing effect. The probability of continuing MTX therapy for up to 2 years was 65% and for up to 5 years was 46%. Adverse effects of MTX occurred in 37.1% of the patients, but only 15.7% discontinued MTX permanently.

UR - http://www.scopus.com/inward/record.url?scp=0026041522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026041522&partnerID=8YFLogxK

M3 - Research Article

C2 - 1757932

AN - SCOPUS:0026041522

SN - 0315-162X

VL - 18

SP - 1323

EP - 1327

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 9

ER -

Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases

Resumen

Áreas temáticas de ASJC Scopus

Otros archivos y enlaces

Huella

Citar esto